Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 3/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.33 |
| ▸ | GUSB | P08236 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 4/20 | 0.31 |
| ▸ | HTR2C | P28335 | 3/20 | 0.31 |
| ▸ | HTR2B | P41595 | 3/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.30 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.30 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1735695 | 1.00 | AR (0.35) | ARBRD4CREBBPGUSBHTR2A | |
| SCHEMBL1735451 | 1.00 | AR (0.35) | ARBRD4CREBBPGUSBHTR2A | |
| SCHEMBL13478819 | 0.86 | AR (0.37) | ARBRD4CREBBPKMT2A | |
| SCHEMBL1735758 | 0.85 | AR (0.36) | ARBRD4CREBBPKMT2A | |
| SCHEMBL1735757 | 0.85 | AR (0.36) | ARBRD4CREBBPKMT2A | |
| SCHEMBL12066676 | 0.85 | AR (0.36) | ARBRD4CREBBPKMT2A | |
| SCHEMBL1735760 | 0.85 | AR (0.36) | ARBRD4CREBBPKMT2A | |
| SCHEMBL1735462 | 0.84 | AR (0.32) | ARKMT2AAPOBEC3AAPOBEC3G | |
| SCHEMBL12156896 | 0.78 | AR (0.38) | ARBRD4CREBBPKMT2A | |
| SCHEMBL1735446 | 0.78 | AR (0.43) | ARBRD4CREBBPHTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8084611-B2 | Process for preparing tetrahydroquinoline derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-12-27 | — | — | US | claimed |
| EP-2007728-B1 | A PROCESS FOR PREPARING TETRAHYDROQUINOLINE DERIVATIVES | MITSUBISHI TANABE PHARMA CORP (JP) | 2011-11-16 | — | — | EP | claimed |
| WO-2011131370-A1 | MELT-GRANULATED FINGOLIMOD | RATIOPHARM GMBH (DE) | 2011-10-27 | — | — | WO | claimed |
| US-20090292125-A1 | PROCESS FOR PREPARING TETRAHYDROQUINOLINE DERIVATIVES | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-11-26 | — | — | US | claimed |
| EP-2007728-A1 | A PROCESS FOR PREPARING TETRAHYDROQUINOLINE DERIVATIVES | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-12-31 | — | — | EP | claimed |
| WO-2007116922-A1 | A PROCESS FOR PREPARING TETRAHYDROQUINOLINE DERIVATIVES | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-10-18 | — | — | WO | claimed |
| US-8084611-B2 | Process for preparing tetrahydroquinoline derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-12-27 | — | — | US | disclosed |
| EP-2007728-B1 | A PROCESS FOR PREPARING TETRAHYDROQUINOLINE DERIVATIVES | MITSUBISHI TANABE PHARMA CORP (JP) | 2011-11-16 | — | — | EP | disclosed |
| WO-2011131370-A1 | MELT-GRANULATED FINGOLIMOD | RATIOPHARM GMBH (DE) | 2011-10-27 | — | — | WO | disclosed |
| EP-2154132-A1 | A process for preparing tetrahydroquinoline derivatives | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-02-17 | — | — | EP | disclosed |
| US-20090292125-A1 | PROCESS FOR PREPARING TETRAHYDROQUINOLINE DERIVATIVES | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-11-26 | — | — | US | disclosed |
| EP-2007728-A1 | A PROCESS FOR PREPARING TETRAHYDROQUINOLINE DERIVATIVES | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-12-31 | — | — | EP | disclosed |
| WO-2007116922-A1 | A PROCESS FOR PREPARING TETRAHYDROQUINOLINE DERIVATIVES | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090292125-A1 | PROCESS FOR PREPARING TETRAHYDROQUINOLINE DERIVATIVES | PCSK9, LSS, DHCR7 | AR 3705/4885BRD4 210/4885CREBBP 4294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.